<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646071</url>
  </required_header>
  <id_info>
    <org_study_id>NP-102</org_study_id>
    <nct_id>NCT03646071</nct_id>
  </id_info>
  <brief_title>A Study of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-label Study of the Safety, Pharmacokinetics and Efficacy of RX108 in Patients With Locally Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuPharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RX108 is a novel, potent, small-molecule inhibitor of Na+/K+-ATPase. The purpose of this
      study is to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of RX108 in
      patients with locally advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a open-label, two-part study comprised of a dose escalation part and a dose expansion
      part. In the dose escalation part, RX108 will be administered in ascending doses to evaluate
      the safety and tolerability of RX108 and determine the maximum tolerated dose (MTD) and/or
      recommended Phase 2 dose (RP2D). The dose expansion part will assess the safety,
      pharmacokinetics, and efficacy of RX108 at the RP2D.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Maximum tolerated dose (MTD) of RX108</measure>
    <time_frame>Day 1 to 30</time_frame>
    <description>All patients treated with RX108 across all dosing levels will have safety assessed in order to determine the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Incidence of adverse events (AEs) and serious adverse events (SAEs).</measure>
    <time_frame>Day 1 to 30 days post last dose</time_frame>
    <description>The incidence of adverse events (AEs) and serious adverse events (SAEs) for each cohort dose will be assessed using CTCAE v 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of RX108</measure>
    <time_frame>Day 1 and Day 3: Hours 0, 1, 2, 3, 5, 8</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach maximum concentration (Tmax)</measure>
    <time_frame>Day 1 and Day 3: Hours 0, 1, 2, 3, 5, 8</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Day 1 and Day 3: Hours 0, 1, 2, 3, 5, 8</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (T1/2)</measure>
    <time_frame>Day 1 and Day 3: Hours 0, 1, 2, 3, 5, 8</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic clearance (CL)</measure>
    <time_frame>Day 1 and Day 3: Hours 0, 1, 2, 3, 5, 8</time_frame>
    <description>Pharmacokinetics parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (per RECIST v1.1)</measure>
    <time_frame>Screening and every 2 cycles for the first 6 cycles and every 3 cycles thereafter (each cycle is 28 days), assessed up to 24 months.</time_frame>
    <description>Evaluate the preliminary efficacy of RX108 in subjects with locally advanced or metastatic solid tumors (subjects with measurable disease in Part 2).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Dose-Escalation Phase will employ a standard 3+3 algorithm to investigate ascending dose cohorts of RX108.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the Expansion Phase, subjects will receive RX108 at the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RX108</intervention_name>
    <description>RX108</description>
    <arm_group_label>Dose Escalation Phase</arm_group_label>
    <arm_group_label>Dose Expansion Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic cancer that has failed all
             systemic therapies known to confer clinical benefit

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Minimum age of 18 years

          -  Adequate hematologic, hepatic and renal function

          -  Written Informed Consent

          -  Must agree to use adequate contraception (females and males)

        Exclusion Criteria:

          -  History of certain cardiac abnormalities

          -  History of inadequate pulmonary function

          -  Symptomatic brain metastasis

          -  Treatment with prohibited medications

          -  Known contra-indication to digoxin

          -  Treatment with any unapproved therapies for cancer, or any other anti-cancer therapy
             within 3 weeks

          -  Any toxicity related to prior treatment must have resolved to Grade 1 or less, with
             the exception of alopecia

          -  Clinically significant active infection requiring systemic antibiotic treatment

          -  Females who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lyon Gleich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lyon Gleich, MD</last_name>
    <phone>(513) 579-9911</phone>
    <phone_ext>12400</phone_ext>
    <email>l.gleich@medpace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa Cajahuaringa</last_name>
      <phone>310-967-2795</phone>
      <email>vanessa.cajahuaringa@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Monica Mita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas at MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lidong Liu, PhD</last_name>
      <email>lliu8@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Siqing Fu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Advanced</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To be determined.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

